- Home
- AMSF vs ABUS Comparison
AMSF vs ABUS Comparison
Compare AMSF & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- ABUS
- Stock Information
- Founded
- AMSF 1985
- ABUS 2005
- Country
- AMSF United States
- ABUS United States
- Employees
- AMSF N/A
- ABUS N/A
- Industry
- AMSF Accident &Health Insurance
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- ABUS Health Care
- Exchange
- AMSF Nasdaq
- ABUS Nasdaq
- Market Cap
- AMSF 758.5M
- ABUS 906.7M
- IPO Year
- AMSF 2005
- ABUS N/A
- Fundamental
- Price
- AMSF $41.12
- ABUS $4.60
- Analyst Decision
- AMSF Buy
- ABUS Strong Buy
- Analyst Count
- AMSF 3
- ABUS 2
- Target Price
- AMSF $58.33
- ABUS $5.00
- AVG Volume (30 Days)
- AMSF 125.1K
- ABUS 905.3K
- Earning Date
- AMSF 10-29-2025
- ABUS 11-06-2025
- Dividend Yield
- AMSF 6.32%
- ABUS N/A
- EPS Growth
- AMSF N/A
- ABUS N/A
- EPS
- AMSF 2.60
- ABUS N/A
- Revenue
- AMSF $309,746,000.00
- ABUS $15,416,000.00
- Revenue This Year
- AMSF $3.54
- ABUS $138.02
- Revenue Next Year
- AMSF $4.84
- ABUS N/A
- P/E Ratio
- AMSF $15.58
- ABUS N/A
- Revenue Growth
- AMSF N/A
- ABUS 53.23
- 52 Week Low
- AMSF $39.09
- ABUS $2.71
- 52 Week High
- AMSF $60.24
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- AMSF 48.74
- ABUS 54.22
- Support Level
- AMSF $39.79
- ABUS $4.34
- Resistance Level
- AMSF $40.92
- ABUS $4.62
- Average True Range (ATR)
- AMSF 0.90
- ABUS 0.20
- MACD
- AMSF 0.12
- ABUS -0.01
- Stochastic Oscillator
- AMSF 64.74
- ABUS 48.18
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.